IBI-3004

N/A

Report date: 2026/01/08 20:00:10

Base Information

Drug NameIBI-3004

Drug Alias NameIBI3004IBI-3004

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionTumor necrosis factor receptor superfamily member 10B agonistsCarcinoembryonic antigen inhibitors

TargetsTumor necrosis factor receptor superfamily member 10BCarcinoembryonic antigen

Therapy Area/IndicationsSolid tumoursColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustraliaMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesInnovent Biologics(Suzhou) Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesInnovent Biologics(Suzhou) Co Ltd

Inactive CompaniesN/A

Active IndicationsColorectal Neoplasms

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A